BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

VigeneTech And Research Groups At NIH / National Cancer Institute And FDA Announce The Deployment Of MicroVigeneTM 2.0 For Reserve Phase Protein Microarray Analysis


10/19/2005 5:10:38 PM

MicroVigeneTM 2.0 extends VigeneTech’s flagship microarray image analysis software to support Reserve Phase Protein Microarray analysis. The new release is a result of close collaboration between VigeneTech and the inventors of the Reverse Phase Protein Microarray methodology -the teams of Dr. Lance Liotta, Chief, Laboratory of Pathology, NIH/NCI and Dr. Emanuel Petricoin, Co-Director, NCI-FDA Clinical Proteomics Program. Scientists of both research teams are now routinely using the software. MicroVigeneTM 2.0 significantly speeds up the data analysis process of the Reserve Phase Protein Microarray analysis, offers powerful tools to support various image layouts and dilution curve designs, and brings this exciting technology to a new level of implementation whereby reproducibility, precision and accuracy can be analyzed very quickly. The deployment of MicroVigeneTM 2.0 is a significant step toward high quality and reproducible standard procedure of Reverse Phase Protein Microarray analysis for the NCI-FDA clinical proteomics program and eventual clinical implementation.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES